Example: bankruptcy
NEW ZEALAND DATA SHEET - Medsafe
2 Systematic evaluation of bupropion hydrochloride 300 mg/day for the prevention of relapse demonstrated that treatment for up to 1 year was well tolerated and
Information
Domain:
Source:
Link to this page:
Documents from same domain
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
Related documents
MODERATE SEDATION MODULE - EduTracker
edutracker.comIntroduction The purpose of this program is to provide the professional nurse with information necessary to safely and appro-priately care for a patient receiving moderate/conscious sedation within the healthcare setting.
Alcohol misusers AWS WE guideline FINAL
www.guysandstthomas.nhs.ukDetection of alcohol misusers, management of alcohol withdrawal syndrome and Wernicke’s Encephalopathy DTC Reference 10052a Page 2 of 17 Review by June2012
The Patient Health Questionnaire-2 (PHQ-2) - …
cqaimh.orgThe Patient Health Questionnaire-2 (PHQ-2) - Overview The PHQ-2 inquires about the frequency of depressed mood and anhedonia over the past two weeks.
![[Product Monograph Template - Standard]](/cache/preview/b/5/6/4/6/9/f/8/thumb-b56469f81fe4cee7737b379eed8967bf.jpg)
[Product Monograph Template - Standard]
www.leo-pharma.cainnohep® (tinzaparin sodium) Product Monograph, version 7.0 Page 6 of 36 Post-Surgical Bleeding: As with all antithrombotic agents, there is a risk of systemic bleeding with INNOHEP. Care should be taken with INNOHEP use in high dose treatment of newly
PRODUCT INFORMATION Paxam - Medicines
www.medicines.org.auPaxam – Product Information 2 between 10 and 80 nanogram/mL. In one study with increase in dosage to 5 mg/day, the average level of …